Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Belimumab + Rituximab for Kidney Disease
Recruiting1 awardPhase 2
Toronto, Ontario
This trial will enroll approximately 30 participants with primary MN who are not well controlled with their current therapy. Participants will be randomly assigned (by chance, like flipping a coin) to one of two treatment groups.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service